

Alzheimer Disease

New Drugs, Markets & Companies

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

May 2012

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is CEO and consultant at Jain PharmaBiotech. Prof. Jain is the author of 435 publications including 19 books (2 as editor) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. Recent books relevant to the nervous system include “Handbook of Neuroprotection” (Springer, 2011) and “Application of Biotechnology in Neurology” (Springer, 2012).

May 2012
Copyright © 2012 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **<http://pharmabiotech.ch/>**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Clinical Features, Epidemiology and Pathology	21
Introduction	21
Historical aspects	21
Clinical features of Alzheimer disease.....	22
Seven stages of Alzheimer disease.....	24
AD as a terminal illness	26
Detection of AD in the preclinical phase	26
Differentiation of AD from other dementias	26
Differentiation of AD from non-dementing disorders	27
Cerebral insufficiency and AD	28
Memory deficits and preclinical AD	28
Mild cognitive impairment	29
Evolution of diagnostic criteria of AD	31
Revised criteria for the clinical diagnosis of AD	32
Epidemiology	33
Epidemiology of aging	33
Epidemiology of dementia	36
Epidemiology of AD	36
<i>Prevalence of AD according to age</i>	<i>37</i>
<i>Mortality in AD.....</i>	<i>37</i>
Pathophysiology of AD.....	38
Cerebral atrophy and neuronal loss	38
Neuritic plaques and neurofibrillary tangles	38
Sp proteins as markers of neuronal death in AD.....	39
Role of tau in the pathogenesis of AD	39
Amyloid precursor protein	40
<i>Relation of APP mutations to CNS disorders.....</i>	<i>41</i>
<i>Relation of APP to Aβ deposits and pathogenesis of AD</i>	<i>41</i>
<i>APP intracellular domain</i>	<i>43</i>
<i>Role of secretases in amyloid cascade</i>	<i>43</i>
<i>Role of exosomal proteins.....</i>	<i>45</i>
<i>Role of nicastrin.....</i>	<i>45</i>
Neurotoxicity of A β deposits	45
<i>Relation of Aβ deposits to synaptic activity.....</i>	<i>46</i>
<i>Dysfunction of TGF-β signaling accelerates Aβ deposition</i>	<i>46</i>
<i>Role of TMP21 in presenilin complexes and Aβ formation</i>	<i>46</i>
<i>Role of Aβ dimers in the pathogenesis of AD.....</i>	<i>47</i>
<i>Structure-neurotoxicity relationships of Aβ oligomers.....</i>	<i>47</i>
A β deposit and clearance	48
Impairment of mitochondrial energy metabolism	49
<i>Aβ-binding alcohol dehydrogenase links AD to mitochondrial toxicity</i>	<i>49</i>
Neural thread protein	49
Loss of synaptic proteins.....	50
<i>AD and Down syndrome.....</i>	<i>50</i>
<i>Overlapping pathologies of AD and Parkinson disease.....</i>	<i>51</i>
<i>AD and age-related macular degeneration.....</i>	<i>51</i>
<i>Myelin hypothesis of AD.....</i>	<i>51</i>
<i>Blood-brain barrier in AD</i>	<i>51</i>
<i>Blood vessel damage in AD</i>	<i>53</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>53</i>
Factors in pathogenesis of AD.....	53
<i>Aerobic glycolysis and AD</i>	<i>53</i>
<i>Astrocytes and AD.....</i>	<i>54</i>
<i>Axonal transport failure in AD.....</i>	<i>54</i>
<i>Cell-cycle hypothesis</i>	<i>55</i>
<i>Chronic heart failure link with AD.....</i>	<i>55</i>
<i>Creatine and AD</i>	<i>55</i>
<i>Disturbances of interaction of nervous system proteins.....</i>	<i>55</i>
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD</i>	<i>56</i>
<i>Gonadotrophins and AD</i>	<i>56</i>
<i>Glutamate transport dysfunction in AD</i>	<i>56</i>
<i>Innate immune system and AD.....</i>	<i>57</i>
<i>Insulin, diabetes and AD.....</i>	<i>58</i>
<i>Mechanisms underlying cognitive deficits in AD.....</i>	<i>58</i>
<i>Monoamine oxidase and AD.....</i>	<i>59</i>
<i>Neuroinflammation and AD</i>	<i>59</i>

<i>Neurotransmitter deficits</i>	60
<i>Neurotrophic factors</i>	61
<i>NF-κB signaling and the pathogenesis of neurodegeneration</i>	61
<i>Nitric oxide and AD</i>	62
<i>Nogo receptor pathway</i>	64
<i>Oxidative stress and AD</i>	64
<i>Prostaglandins and AD</i>	66
<i>Quinolinic acid and AD</i>	66
<i>Retromer deficiency</i>	66
<i>Serotonin and AD</i>	67
<i>Spherotoxin</i>	67
<i>Synaptic failure in AD</i>	67
<i>Transmission of AD</i>	68
<i>Ubiquitin-proteasome system in pathogenesis of AD</i>	69
Risk factors in the etiology of AD	70
<i>Aging and developmental abnormalities of the cholinergic system</i>	70
<i>Cholesterol, dietary lipids, and Aβ</i>	70
<i>Exposure to magnetic fields</i>	71
<i>Family history of AD</i>	71
<i>Homocysteine and AD</i>	72
<i>Level of education/type of job and risk of AD</i>	72
<i>Metals and AD</i>	73
<i>Obesity</i>	75
<i>Proneness to psychological distress and risk of AD</i>	75
<i>Reduced muscle strength</i>	75
<i>Sleep deprivation</i>	76
<i>Traumatic brain injury and AD</i>	76
<i>Vascular risk factors for AD</i>	77
<i>Vitamin B12 and folate</i>	79
AD versus non-dementing changes in the aging brain.....	79
AD and cognitive impairment with aging	79
Pathomechanism of memory impairment and AD	80
Concluding remarks on pathophysiology of AD.....	80
Genetics of AD	82
Familial AD.....	82
<i>Presenilins and calcium channel leak in pathogenesis of familial AD</i>	83
Late onset AD.....	83
Genomics of AD	84
Introduction to genomics	84
Genes associated with Alzheimer disease	84
<i>AlzGene database</i>	85
<i>ApoE gene</i>	86
<i>ApoE genotype and nitric oxide</i>	87
<i>ApoE genotype modulates AD phenotype</i>	87
<i>APOE genotype and age-related myelin breakdown</i>	88
<i>ApoE receptor interaction with NMDA receptor</i>	88
<i>ApoE and ApoER2</i>	88
<i>ApoE receptor LR11 as regulator of Aβ</i>	89
<i>Arctic mutation</i>	89
<i>CALHM1 polymorphism and AD</i>	89
<i>CLU, CRI and PICALM</i>	90
<i>CYP46 and risk for AD</i>	90
<i>DAPK1 gene variants and AD</i>	90
Genetic variants associated with late-onset AD	91
<i>Copy number variation (CNV) in LOAD</i>	91
<i>LRRTM3 as a candidate gene for AD</i>	91
<i>MTHFD1L gene variant associated with AD</i>	92
<i>OGG1 mutations associated with AD</i>	92
<i>SORL1 gene in AD</i>	92
<i>TOMM40 gene and risk of AD</i>	92
International Genomics of Alzheimer's Project	93
Sequencing in Alzheimer disease	93
Molecular neuropathology	94
Role of microRNAs in AD	94
AD as a polygenic disorder.....	95
Proteomics of AD	95
Introduction	95
Application of proteomic technologies to study AD.....	95
Protein misfolding in AD.....	97
Common denominators of AD and prion diseases.....	98
<i>Amyloid fibrils as a common feature of AD and prion diseases</i>	99

FE65 proteins and AD	99
----------------------------	----

2. Diagnostic Procedures for Alzheimer Disease	101
Importance of the diagnosis of Alzheimer disease.....	101
Methods of diagnosis of AD.....	101
Self-administered olfactory test	102
Neuropsychological testing	102
Assessment and evaluation	103
7-minute screen	103
15-point risk index.....	104
Measurement of aggregation in anterior segment of the eye.....	104
Activities of Daily Living.....	104
Alzheimer Disease Cooperative Study.....	105
CDR-SOB score.....	105
Clinician's Interview-Based Impression of Change.....	105
Resource Utilization in Dementia Battery.....	105
DETECT™ System.....	105
Electrophysiology.....	106
EEG-based bispectral index	106
Event-related potentials.....	106
Correlation of electrical activity of the brain with cognition	106
Early detection of cataract associated with AD	107
Retinal imaging to detect A β deposits	107
Laboratory methods for diagnosis of AD.....	107
Monitoring of synthesis and clearance rates of A β in the CSF.....	107
Molecular diagnostics for AD.....	108
Genetic tests for AD	109
ApoE genotyping.....	109
Gene expression patterns in AD.....	110
Molecular fingerprinting of the immune system in AD	110
Microarray-based tests for AD	110
Monoclonal antibody-based in vitro diagnosis of AD from brain tissues	111
Biomarkers of AD.....	111
The ideal biomarker for AD.....	113
CSF biomarkers of AD	113
CSF sulfatide as a biomarker for AD	113
Glycerophosphocholine as CSF biomarker in AD	114
Protein biomarkers of AD in CSF	114
Amyloid precursor protein	116
Tau proteins in CSF.....	116
Tests for the detection of A β in CSF.....	116
Tests combining CSF tau and A β	117
Urine tests for AD	117
Blood tests for AD	118
Blood A β levels	118
Blood test for AD based on heme oxygenase-1	119
Blood test for AD based on RNA hybridization	119
GSK-3 elevation in white blood cells.....	119
Lymphocyte Proliferation Test.....	120
MGAT3 as biomarker for prognosis of AD	120
Protein kinase C in red blood cells.....	120
Sphingolipids.....	120
Tests based on protein biomarkers in blood.....	121
A skin test for early detection of AD	121
Saliva-based tests for AD.....	122
Saliva A β 42 level as a biomarker of AD.....	122
Nanotechnology to measure A β -derived diffusible ligands	122
Simultaneous measurement of several biomarkers for AD	123
Plasma biomarkers of drug response in AD.....	123
A serum protein-based algorithm for the detection of AD	123
Concluding remarks about biomarkers for AD	124
Imaging in AD.....	124
Computed tomography	124
Magnetic resonance imaging	125
Arterial spin labeling with MRI	125
Magnetic resonance microscopy	126
Magnetic resonance spectroscopy	126
Single photon emission computed tomography and modifications.....	127
Positron emission tomography	127
In vivo imaging of A β deposits by PET	129
Pittsburgh compound B and PET	129

<i>Florbetapir-PET</i>	130
<i>Florbetaben-PET</i>	131
In vivo detection of A β plaques by MRI.....	131
Imaging agents for A β and neurofibrillary tangles.....	132
Targeting of a chemokine receptor as biomarker for brain imaging.....	132
Radioiodinated clioquinol as a biomarker for A β	133
Imaging neuroinflammation in AD.....	133
Preclinical diagnosis of AD.....	133
Meta-analysis of literature on imaging in AD.....	134
Alzheimer Disease Neuroimaging Initiative.....	134
Concluding remarks on imaging for diagnosis of AD.....	135
Diagnosis of MCI and prediction of AD.....	135
Diagnosis of MCI.....	135
<i>Computer-Administered Neuropsychological screen for MCI</i>	136
<i>Infrared eye-tracking technology to detect MCI</i>	136
<i>PET for detection of MCI</i>	136
<i>MRI for detection of MCI</i>	137
Presymptomatic detection of AD.....	137
PredictAD project.....	137
Prediction of AD in patients with MCI.....	138
<i>Combination of MMSE and a memory test for prediction of AD</i>	138
<i>Biochemical biomarkers in CSF for prediction of AD</i>	138
<i>Structural MRI biomarkers for prediction of AD</i>	138
<i>Magnetoencephalography for detection of MCI and AD</i>	139
<i>Concluding remarks about prediction of AD in MCI</i>	140
Criteria for diagnosis of AD.....	140
Role of biomarkers in diagnosis of AD dementia.....	140
Ethical aspects of diagnostics for AD.....	141
Genetic testing for AD.....	141
Ethical issues of brain imaging in AD.....	141
Companies involved in diagnosis of AD.....	142
3. Management of Alzheimer Disease.....	145
Introduction.....	145
Cholinergic approaches.....	145
Mechanism of action of cholinesterase inhibitors.....	146
Choline and lecithin.....	147
Donepezil.....	148
Rivastigmine.....	149
Galantamine.....	150
Duration of treatment with ChE inhibitors.....	151
Comparative studies of ChE inhibitors.....	151
Donepezil versus rivastigmine.....	152
Donepezil versus galantamine.....	152
An assessment and future prospects of anticholinergic therapies.....	152
Neuroprotection in Alzheimer's disease.....	153
Memantine.....	154
<i>Combination of memantine with ChE inhibitors</i>	157
Monoamine oxidase inhibitors.....	158
<i>Selegiline</i>	158
Synaptoprotection in AD.....	158
Drugs for noncognitive symptoms in AD.....	158
Antidepressants.....	159
Antipsychotics.....	159
ChE inhibitors for behavioral and psychological disorders in AD.....	159
Concluding remarks and other drugs for agitation in AD.....	160
Sensory stimulation.....	161
Non-pharmacological treatments of AD.....	161
Management of memory loss in AD.....	161
Exposure to electromagnetic fields for treatment of AD.....	162
<i>Application of electrical fields for improvement of cerebral function</i>	162
<i>High-frequency electromagnetic field treatment of AD</i>	162
Vagal nerve stimulation.....	163
Cerebrospinal fluid shunting.....	163
Omental transposition.....	164
Microchip-based hippocampal prosthesis for AD.....	164
Nutritional therapies for AD.....	164
Axona.....	164
<i>Cocktail of dietary supplements for AD</i>	164
<i>Docosahexaenoic acid</i>	165
Magnesium.....	166

<i>Nicotinamide for the treatment of AD</i>	167
<i>Omega-3 fatty acids</i>	167
Preventing decline of mental function with aging and dementia	168
Prevention of Alzheimer disease	168
<i>Mental training</i>	169
<i>Physical exercise</i>	170
<i>Higher level of conscientiousness and decreased risk of AD</i>	170
<i>Caloric restriction</i>	171
<i>Nutritional factors in prevention of AD</i>	171
<i>Grapes and red wine</i>	171
<i>Black and green teas</i>	173
<i>Caffeine</i>	173
Drugs to prevent Alzheimer disease	173
Preimplantation genetic diagnosis of inherited Alzheimer disease	173
Presymptomatic detection of AD	174
Management of mild cognitive impairment	174
Management of Down syndrome	175
Guidelines for use of anti-dementia drugs in clinical practice	176
Donepezil and/or memantine.....	177
General care of the Alzheimer disease patients	177
Strategies for the management of Alzheimer disease	177
4. Research in Alzheimer Disease	180
Introduction	180
Animal models of Alzheimer disease	180
Lesional models	180
<i>Cerebroventricular injection of Aβ in rats</i>	180
<i>Lentiviral vector-based models of amyloid pathology</i>	181
<i>AAV-mediated gene transfer to increase hippocampal Aβ</i>	181
Transgenic mouse models	181
<i>Quantitative assessment of amyloid load in transgenic models</i>	183
<i>In vivo magnetic resonance microimaging in transgenic models of AD</i>	183
<i>Transgenic model of AD with suppression of Aβ production</i>	183
<i>Transgenic AD11 anti-NGF mice</i>	184
<i>Genetically altered mice with deficiency of vesicular ACh transporter</i>	184
<i>Limitations of mouse models of Alzheimer disease</i>	184
Cholesterol-fed rabbits as models for AD.....	185
Zebrafish model for AD	185
Transgenic invertebrate models of Alzheimer disease	186
<i>Drosophila model of AD</i>	186
<i>Caenorhabditis elegans Alzheimer disease model</i>	187
Cell systems for AD research	187
In vitro neuronal cell Lines	187
Single-gene expression system for use in cell culture	188
Transgenic cells	188
In silico models	189
Estimation of progression rates of Alzheimer disease	189
Clinical trial methods in Alzheimer disease	190
Molecular imaging as a guide to drug development	190
<i>Use of MRI and PET in clinical trials</i>	191
Cognitive-function assessment in clinical trials.....	191
Clinical trials in mild cognitive impairment.....	192
Research in AD as a basis for future therapies	192
Use of microarrays for studying pathogenesis of AD	192
Computational brain mapping in AD	192
Study of neurogenesis in AD	193
Study of 3D structure of A β	193
Solid-state NMR to study precursors of A β	193
Research in Alzheimer disease at academic centers	193
Role of NIH in AD research.....	194
NIH Clinical Trials Database for AD.....	194
Alzheimer Research Consortium.....	194
The National Institute on Aging and AD research	194
5. Drug Discovery & Development for Alzheimer Disease	196
Introduction	196
Categories of drugs in development for AD	196
Memory-enhancing drugs	198
Enhancing memory by drugs that block eIF2 α phosphorylation	198
Drugs based on cholinergic approaches	198
AP2238.....	199

Butyrylcholinesterase inhibitors	199
Donepezil-tacrine hybrids.....	199
Drugs modulating gamma-aminobutyric acid receptors.....	200
Ganstigmina.....	200
Methanesulfonyl fluoride	200
Muscarinic receptor modulators	201
<i>Muscarinic M1 agonists</i>	201
<i>Muscarinic M2 antagonists</i>	202
Nicotine and nicotinic receptor modulators	202
<i>Nicotine</i>	202
<i>Nicotinic receptor modulators</i>	203
<i>GTS21</i>	204
<i>Ispronicline</i>	204
<i>JWB1-84-1</i>	205
Neuropeptide/neurotransmitters	205
Somatostatin release enhancers	205
Glutamate receptor modulators	205
Physiology and pharmacology of glutamate receptors.....	206
NMDA receptor ion channel complex.....	206
Metabotropic glutamate receptors	208
Glutamate receptor modulators as potential therapeutics for AD	209
<i>Non-competitive NMDA modulators</i>	210
<i>AMPA modulators</i>	210
Drugs affecting multiple neurotransmitters.....	211
Ensaculin	211
NS2330	211
RS-1259	211
Lecozotan	212
Vaccines for AD.....	212
Active immunization with A β	213
<i>AN-1792 vaccine</i>	213
<i>Complications in clinical trials with AN-1792</i>	213
<i>Effects of Aβ vaccine on the brain</i>	213
Strategies to avoid undesirable effect of A β vaccination	214
Passive immunization in AD.....	215
<i>Passive immunization with MAbs</i>	215
<i>Delivery of the passive antibody directly to the brain</i>	217
<i>Systemic injection of MAbs to treat AD</i>	218
Combination of A β immunotherapy and CD40-CD40L blockade	218
Shaping the immune responses elicited against A β	218
Delivery of AD vaccines	219
<i>Gene vaccination</i>	219
<i>Modified Aβ nasal vaccine</i>	219
<i>Transdermal Aβ vaccination</i>	219
Other vaccines for AD.....	220
<i>Nasal vaccination with Proteosome™ adjuvant</i>	220
<i>T-cell vaccination with glatiramer acetate adjuvant</i>	221
Early start of immunotherapy to clear A β plaques	221
Reversal of cholinergic dysfunction by anti-A β antibody	221
Immune modulation via TRL9 to reduce A β	221
Mechanisms by which A β antibodies reduce amyloid accumulation in the brain	222
Perspectives on vaccines for AD.....	222
Companies involved in AD vaccines	224
Inhibition of amyloid precursor protein aggregation	225
Secretase modulators.....	225
<i>Neuroprotection by α-secretase cleaved APP</i>	226
<i>Inhibitors of β-secretase</i>	226
<i>Inhibitors of γ-secretase</i>	227
Amyloid-derived diffusible ligands	228
GABA receptor modulation by etazolate and APP processing	229
Depletion of serum amyloid P.....	229
Trojan-horse approach to prevent build-up of A β aggregates.....	229
Drugs that inhibit the formation of Aβ	230
22R-hydroxycholesterol	230
Acylaminopyrazole	231
Cadmium telluride nanoparticles prevent A β fibril formation	231
Cannabinoids.....	231
Chelation therapy for AD.....	232
<i>Clioquinol and PBT2</i>	232
<i>Copper chelation by FKBP52</i>	233
<i>Zinc chelation from amyloid plaques</i>	234

<i>Next generation multifunctional chelating agents for AD</i>	234
Heparin and its derivatives.....	234
<i>A reassessment of the role of heparin in AD</i>	234
<i>Enoxaparin</i>	235
<i>Heparan sulfate</i>	235
Imatinib mesylate	235
Laminin	236
NSAIDs.....	236
<i>Flurbiprofen analogs with Aβ42-lowering action</i>	237
<i>Nitric oxide-donating NSAIDs</i>	238
<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i>	238
Paclitaxel	238
Phenserine	239
<i>Tolserine</i>	239
Platinum-based inhibitors of A β	240
Scyllo-cyclohexanehexol	240
Ubiquitin C-terminal hydrolase L1	240
Drugs to prevent the formation of NFTs.....	240
Tau suppression.....	241
ApoE4 as a therapeutic target in AD	242
Strategies to prevent deposits and enhance clearance of Aβ	242
4,5-dianilinophthalimide for disruption of A β ₁₋₄₂ fibrils.....	243
ABCA1 overexpression to lower amyloid deposits	244
Beta-sheet breakers	244
Blocking ApoE/A β interaction to reduce A β plaques	244
Clearance of A β across the blood-brain barrier.....	245
Enhanced PKC ϵ activity promotes clearance of A β	245
Galantamine-induced A β clearance.....	245
Inhibitors of A β dehydrogenase	246
Intravenous immune globulin	246
Meptides.....	247
Monoclonal antibodies for removal of A β	247
<i>Crenezumab</i>	247
<i>Gantenerumab</i>	248
<i>Solanezumab</i>	248
Nanotechnology for removal of A β deposits	248
Role of matrix metalloproteinases in clearance of A β	248
SAN-61 for cleavage of fibril and soluble amyloid	249
Serum amyloid P component depletion	249
Small molecule DAPH for clearance of amyloid.....	249
Companies developing Aβ-directed therapeutics for AD	250
Antiinflammatory and antimicrobial drugs.....	251
Dapsone	251
Antimicrobial drugs against <i>C. pneumoniae</i>	252
PPAR-gamma agonists.....	252
Inhibitors of neuroinflammation	252
<i>Cyclophosphamide</i>	252
<i>Etanercept</i>	253
<i>MW01-5-188WH</i>	253
Antidiabetic drugs.....	254
Rosiglitazone.....	254
Pioglitazone.....	254
Nootropics	255
Acetyl-L-carnitine.....	255
Cerebrolysin	255
Ergot derivatives.....	256
<i>Lisuride</i>	256
<i>Dihydroergocryptine</i>	256
Neuroprotective effect drugs not primarily developed for AD	256
Antihypertensive drugs	257
<i>Angiotensin-converting enzyme inhibitors</i>	257
<i>Angiotensin receptor blockers</i>	258
Dimebon.....	258
Drugs acting on estrogen receptors	259
<i>Estrogen</i>	259
<i>Raloxifene</i>	260
Neurosteroids.....	260
<i>Pregnenolone sulfate</i>	260
<i>Dehydroepiandrosterone</i>	261
Lithium	261
MAO-B inhibitors.....	261

<i>Ladostigil tartrate</i>	262
<i>Memoquin</i>	262
Methylene blue	262
Nimodipine.....	263
Rapamycin	263
Statins.....	264
Testosterone	264
Valproic acid.....	265
Future prospects of neuroprotection in AD.....	266
<i>Targeting Cdk5 pathway</i>	266
Antioxidants	267
Colostrinin	267
Curcumin	267
Dehydroascorbic acid	268
Melatonin	269
Omega-3 fatty acids.....	269
Reservatrol	269
Synthetic catalytic scavengers.....	270
Vitamins	270
Vitamin E as antioxidant	270
Vitamins to lower homocysteine.....	270
Folic acid	271
Aminopyridazines	271
Nanobody-based drugs for AD	271
Nitric oxide based therapeutics for AD.....	272
Nitric oxide mimetics	272
iNOS inhibitors for AD.....	272
Novel drugs for AD from natural resources	273
Berberine chloride.....	273
Centella asiatica	274
Ginko biloba.....	274
Huperzine-A	275
Hyperforin.....	276
Melissa officinalis	276
Nostocarboline derived from cyanobacteria	276
PTI-00703.....	277
Salvia.....	277
Securinega suffruticosa.....	277
Withania somnifera	277
ZT-1.....	278
Cholesterol and AD	278
ACAT inhibitors.....	279
Role of gene for cholesterol ester transfer protein	280
Cholesterol 24S-hydroxylase as a drug target for AD.....	280
Selectively increase of ApoA-I production.....	280
Neurotrophic factors.....	281
Activity-dependent neuroprotective protein	281
Brain derived neurotrophic factor	281
Insulin-like growth factor-1	281
Nerve growth factor	282
Neotrofin (AIT-082).....	283
Limitations of the use of NTFs for AD.....	283
Role of serotonin modulators in AD	284
Xaliproden	284
5-HT _{1A} receptor antagonists	284
5-HT ₆ antagonists	284
5-HT ₄ receptor agonists	285
<i>PRX-03140</i>	285
Cell therapy for AD.....	286
Stem cell transplantation for AD	286
<i>Potential benefits of grafting NSCs in AD</i>	286
<i>NSCs improve cognition in AD via BDNF</i>	287
<i>Drugs for enhancing neuronal differentiation of implanted NSCs</i>	287
Implantation of encapsulated cells for delivering NGF	287
Gene therapy for AD	287
ApoE gene therapy.....	288
FGF2 gene transfer in AD	288
Humanin gene therapy	288
Nepilysin gene therapy	288
NGF gene therapy	289
Targeting plasminogen activator inhibitor type-1 gene.....	290

Antisense approaches to AD	290
RNAi approaches to AD	291
Combined therapeutic approaches to AD	292
Drug delivery for Alzheimer disease	292
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	292
Nanoparticle-based drug delivery for Alzheimer's disease.....	293
Transdermal drug delivery in Alzheimer's disease.....	294
<i>Transdermal rivastigmine.....</i>	294
Intranasal delivery of therapeutics for AD	294
<i>Intranasal delivery of tacrine.....</i>	294
<i>Intranasal delivery of nerve growth factor to the brain.....</i>	295
Circadian rhythms and timing of cholinesterase inhibitor therapy	295
Clinical trials for AD	295
Drugs for AD that were discontinued in clinical trials	300
Evaluation of clinical trials of AD	302
Monitoring of cognitive function during clinical trials	303
Drug discovery for AD	303
Drugs acting on signaling pathways	303
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1</i>	303
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD</i>	304
<i>Inhibition of the CD40 signaling pathway</i>	304
<i>JNK pathway as a target.....</i>	305
<i>Mitogen-activated protein kinase pathway as target</i>	305
<i>Protein kinase C activators.....</i>	305
Electrophysiological detection of drug target for neuroprotection in early AD	306
Genomics-based drug discovery.....	306
High through screening for AD drug candidates	306
Proteomics and drug discovery for AD	307
Small molecule compounds binding to neurotrophin receptor p75NTR.....	308
<i>Targeting Vav in tyrosine kinase signaling pathway</i>	308
Novels targets/receptors for AD drug discovery	309
<i>Activation of cerebral Rho GTPases</i>	309
<i>Activators of insulin-degrading enzyme.....</i>	309
<i>Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages</i>	309
<i>Calcium channel blockers.....</i>	310
<i>Casein kinase 1</i>	310
<i>Cyclin-dependent kinase-5.....</i>	311
<i>Heat shock protein 90 inhibitors.....</i>	311
<i>Histone deacetylase 1.....</i>	311
<i>Inactivation of aph-1 and pen-2 reduces APP cleavage</i>	312
<i>NF-κB inhibitors.....</i>	312
<i>Kinases and phosphatases as targets for AD therapeutics</i>	312
<i>Neutral sphingomyelinase inhibitors</i>	313
<i>Phosphodiesterase inhibitors</i>	313
<i>Pin 1 as a target in AD.....</i>	313
<i>Protein phosphatase 5 as a neuroprotective in AD.....</i>	314
<i>Src homology-containing protein-1 inhibitors.....</i>	314
<i>Targeting GABAergic system</i>	314
Pharmacogenomics of Alzheimer disease	315
Personalized therapy of AD	315
Genotyping and AD therapeutics.....	315
Biomarkers and companion diagnostics for AD.....	316
Regulatory aspects of drug development for AD	317
EMA guidelines for drug development for AD	317
Concluding remarks and future prospects of drugs for AD.....	317
6. Markets & Finances of AD Care	319
Introduction	319
Pharmacoeconomics of treatment of AD	319
Quality of Life in relation to economics of AD.....	319
Costs associated with Alzheimer disease	319
Pharmacoeconomics of donepezil	320
Pharmacoeconomics studies using rivastigmine	320
Pharmacoeconomics studies using galantamine	321
A comparison of pharmacoeconomics outcomes with different ChE inhibitors	321
Pharmacoeconomics studies using memantine.....	322
Patterns of AD care in major markets.....	322
Care of AD patients in the US	322
<i>Cost of care.....</i>	322
<i>Medicare and AD.....</i>	323
<i>Patterns of practice in AD care.....</i>	324

<i>Opinions of physicians' organizations on drugs for dementia</i>	324
Care of AD patients in the UK.....	325
<i>Cost of care</i>	325
<i>Patterns of practice in AD care</i>	325
<i>Retraction of NICE recommendations to NHS</i>	326
Care of AD patients in Germany.....	327
Care of AD patients in France.....	327
Care of AD patients in Italy.....	328
Care of AD patients in Spain.....	328
Care of AD patients in Japan.....	328
Markets for AD diagnostics	329
Markets for AD therapeutics	329
Geographical markets for AD.....	329
Markets for currently approved drugs for AD.....	330
Markets for generic AD drugs.....	330
Future growth of AD market.....	331
Statins.....	331
Limitations of AD drug development by the biotechnology industry	331
Unmet needs in the management of AD	332
Drivers of AD markets	333
Increase of the aged populations.....	334
Increase in the number of approved drugs for AD.....	334
Limitations of the current therapies.....	334
Improvements in diagnosis.....	334
Increasing awareness of the disease.....	335

7. Companies	337
Introduction	337
Profiles of companies	337
Abbott Laboratories.....	338
AC Immune SA.....	339
Accera Inc.....	341
Actelion Ltd.....	342
Acumen Pharmaceuticals Inc.....	343
Addex Pharmaceuticals.....	344
Adlyfe Inc.....	345
Advanced Life Sciences.....	346
Affiris GmbH.....	347
Allon Therapeutics Inc.....	348
AlzProtect.....	349
Amgen Inc.....	350
Amorfix Life Sciences Ltd.....	351
Applied NeuroSolutions Inc.....	352
Archer Pharmaceuticals Inc.....	353
AstraZeneca.....	354
Athena Diagnostics Inc.....	355
Avera Pharmaceuticals Inc.....	356
Avid Radiopharmaceuticals Inc.....	357
Avineuro Pharmaceuticals Inc.....	358
Axon Neuroscience.....	359
Bayer Healthcare.....	360
Baxter Healthcare International Inc.....	361
Bellus Health Inc.....	362
BioArctic Neuroscience AB.....	363
BiOasis Technologies Inc.....	364
BioE Inc.....	365
Boehringer Ingelheim GmbH.....	366
Bristol-Myers Squibb Company.....	367
BTG International Ltd.....	368
CALBIOCHEM.....	369
Cellzome AG.....	370
CEPHALON Inc.....	371
Ceregene Inc.....	372
Chiesi Farmaceutici SpA.....	373
Circadian Technologies Ltd.....	374
CoMentis Inc.....	375
Cortex Pharmaceuticals Inc.....	376
Cortica Neurosciences.....	377
Crossbeta Biosciences BV.....	378
Curaxis Pharmaceutical Corporation.....	379
Cyberonics Inc.....	380

Cytos Biotechnology AG	381
D-Pharm	382
Dainippon Sumitomo Pharma	383
Debiopharm SA	384
Diamedica Inc	385
Digilab BioVisioN GmbH	386
Ebewe Pharma GmbH	387
Eisai Co Ltd	388
Eli Lilly & Co	389
ENKAM Pharmaceuticals A/S	390
EnVivo Pharmaceuticals	391
EPIX Pharmaceuticals	392
Evotec AG	393
ExonHit Therapeutics SA	394
FluoroPharma Inc	395
Forest Laboratories Inc	396
Galantos Pharma GmbH	397
Galapagos Genomics	398
GE Healthcare Ltd	399
Genentech Inc	400
GlaxoSmithKline	401
H. Lundbeck A/S	402
Helicon Therapeutics Inc	403
Hoffmann-La Roche Ltd	404
Humanetics Corporation	405
Innogenetics NV	406
Intellect Neurosciences Inc	407
IntelliHep Ltd	408
Interleukin Genetics Inc	409
Intra-Cellular Therapies Inc	410
ItherX	411
JANSSEN Alzheimer Immunotherapy	412
Lay Line Genomics	413
Lexicon Genetics Incorporated	415
Maas BiolAB LLC	416
Medivation Inc	417
Merck & Co	418
Merz & Co GmbH	419
MIGENIX Inc	420
MindGenix Inc	421
Mindset BioPharmaceuticals Ltd	422
Mithridion Inc	423
MorphoSys AG	424
Myriad Genetics Inc	425
Neurimmune Holding AG	426
Neuro-Hitech Inc	428
Neurologix Inc	429
NeuroMolecular Pharmaceuticals	430
Newron Pharmaceuticals SpA	431
Neuronautics Inc	432
NeuroNascent Inc	433
NeuroNova AB	434
Neuroptix Corporation	435
NeuroSearch	436
Noscira	437
Novartis AG	438
NsGene	439
Nymox Corporation	440
Ortho-McNeil Neurologics Inc	441
Osta Biotechnologies Inc	442
Panacea Pharmaceuticals Inc	443
Pfizer Pharmaceutical Group	444
Pharmexa A/S	445
Pharnext SAS	446
Phytopharm Plc	447
Piramal Healthcare Ltd	448
Prana Biotechnology Limited	449
PrimaBiomed Ltd	450
Probiodrug AG	451
Proneuron Biotechnologies Ltd	452
ProteoTech Inc	453

Provista Life Sciences	454
Raptor Pharmaceuticals Corp	455
Reata Pharmaceuticals Inc	457
ReGen Therapeutics Plc	458
reMYND NV	459
Samaritan Pharmaceuticals Inc.....	460
Sanomune Inc	461
Sanochemia Pharmazeutika AG.....	462
Sanofi-Aventis	463
Satoris Inc	464
Savient Pharmaceuticals Inc.....	465
Schwabe Pharmaceuticals	466
Senexis Limited	467
SeneXta Therapeutics SA	469
Servier	470
Sigma-Tau SpA.....	471
Sygnis Pharma AG	472
Takeda Pharmaceutical Corporation.....	473
Targacept Inc	474
TauRx Pharmaceuticals	475
Teva Pharmaceutical Industries Ltd	476
The Genetics Company	477
Thuris Corporation	478
Toyama Chemical Co Ltd.....	479
Transition Therapeutics Inc	480
Translational Genomics Research Institute	481
TransTech Pharma	482
United Biomedical Inc.....	483
Collaborations.....	485

8. References..... 489

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease.....	21
Table 1-2: Clinical features of Alzheimer disease	22
Table 1-3: Non-Alzheimer dementias	27
Table 1-4: A guide to evaluation for MCI due to AD.....	30
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease	31
Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease	33
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders.....	41
Table 1-8: Risk factors for Alzheimer's disease	70
Table 1-9: Genes linked to AD	84
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD.....	96
Table 2-1: Classification of methods of diagnosis of Alzheimer disease	101
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease	102
Table 2-3: Available molecular diagnostic tests for Alzheimer disease.....	108
Table 2-4: Classification of biomarkers of AD in blood and CSF.....	111
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease	113
Table 2-6: Role of biomarkers in diagnosis of AD dementia	140
Table 2-7: Companies involved in the diagnosis of Alzheimer disease.....	142
Table 3-1: Classification of treatments for Alzheimer disease	145
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease.....	146
Table 3-3: Categories of neuroprotective agents for Alzheimer disease.....	154
Table 3-4: Strategies for prevention of Alzheimer disease.....	169
Table 3-5: Guidelines for the treatment of dementia	176
Table 4-1: Transgenic mouse models of Alzheimer disease	181
Table 5-1: Classification of therapies in development for Alzheimer disease	196
Table 5-2: Drugs for AD targeting nACh receptors	204
Table 5-3: Ionotropic glutamate receptors	206
Table 5-4: Classification of mGluRs.....	206
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD.....	209
Table 5-6: Companies involved in developing vaccines for AD	224
Table 5-7: Secretase modulators in clinical trials	225
Table 5-8: Companies developing A β -directed therapeutics for AD.....	250
Table 5-9: Innovative neuroprotective approaches for Alzheimer disease.....	257
Table 5-10: Herbal therapies for AD	273
Table 5-11: Novel drug delivery methods for Alzheimer disease therapies.....	292
Table 5-12: Clinical trials in Alzheimer disease	295
Table 5-13: Discontinued, failed or inconclusive clinical trials of Alzheimer disease	300

Table 6-1: Direct and indirect costs associated with Alzheimer disease	320
Table 6-2: Prevalence of AD in major markets 2011-2021	329
Table 6-3: AD market values from 2011-2021 in major world markets	330
Table 6-4: Markets for currently approved AD drugs 2011-2021	330
Table 6-5: Potential markets for drugs in development 2011-2021	331
Table 6-6: Limitations of AD drug discovery and development by the biotechnology industry	332
Table 6-7: Factors that drive AD markets	333
Table 7-1: Major players in Alzheimer's disease therapeutics.....	337
Table 7-2: Collaborations relevant to Alzheimer disease	485

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050.	34
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020	35
Figure 1-3: Prevalence of different types of dementia.....	36
Figure 1-4: Mechanisms of A β clearance	48
Figure 1-5: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease	63
Figure 1-6: Oxidative stress and Alzheimer disease.....	65
Figure 1-7: Role of proteasome inhibition in A β generation and neurodegeneration	69
Figure 1-8: Pathomechanism of AD	81
Figure 3-1: Metabolism of acetylcholine.....	147
Figure 3-2: Neuroprotective effective of galantamine in AD	151
Figure 3-3: Strategies for the management of Alzheimer disease.....	179
Figure 5-1: NMDA receptor ion channel complex.....	208
Figure 5-2: Neurotoxicity due to misfolding of A β 1-42	243
Figure 5-3: Role of proteomics in drug discovery/development for Alzheimer disease	307
Figure 6-1: Unmet needs in the management of Alzheimer disease.....	333